PSN632408
PSN632408 Basic information
- Product Name:
- PSN632408
- Synonyms:
-
- PSN632408
- PSN 632408; PSN-632408; PSN 632408; PSN-632408
- tert-butyl 4-((3-(pyridin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)piperidine-1-carboxylate
- 1-Piperidinecarboxylic acid, 4-[[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]methoxy]-, 1,1-dimethylethyl ester
- PSN632408,PSN-632408
- CAS:
- 857652-30-3
- MF:
- C18H24N4O4
- MW:
- 360.41
- Mol File:
- 857652-30-3.mol
PSN632408 Chemical Properties
- Boiling point:
- 513.8±60.0 °C(Predicted)
- Density
- 1.25±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- Soluble in DMSO
- form
- crystalline solid
- pka
- 0.79±0.10(Predicted)
- color
- White to off-white
PSN632408 Usage And Synthesis
Uses
PSN632408, a selective, orally active GPR119 agonist, shows similar potency to OEA at both recombinant mouse and human GPR119 receptors (EC50=5.6 and 7.9 uM, respectively). PSN632408 can stimulate β-cell replication and improve islet graft function. PSN632408 has the potential for the research of obesity and related metabolic disorders[1][2].
Biological Activity
psn632408 is a novel, selective and small-molecule agonist of human and mouse gpr119 with ec50 values of 5.6±0.99 μm and 7.9±0.7 μm, respectively [1].psn632408 has been reported to activate human and mouse gpr119 in a yeast fluorimetric assay with ec50 of 5.6±0.99 μm and 7.9±0.7 μm, respectively. in hek-osgpr116 cells, camp level was dose-dependently increased by psn632408 with an ec50 of 1.9±0.14 μm.. in vivo, psn632408 induced food intake reduction by using a rat feeding model and acute hypophagic effects in dose-dependence [1].
in vivo
PSN632408 (100 mg/kg; p.o.; daily for 14 days) suppresses food intake in rats and reduce body weight gain and white adipose tissue deposition upon subchronic oral administration to high-fat-fed rats[1].
| Animal Model: | Diet-induced obese (DIO) rats[1] |
| Dosage: | 100 mg/kg |
| Administration: | P.o.; daily for 14 days |
| Result: | The mean daily food intake was decreased by 10% during the first week of dosing and 15% during the second week. Body weight gain was significantly attenuated from day 6 onward with some evidence of weight loss. |
References
[1] overton ha1, babbs aj, doel sm, fyfe mc, gardner ls, griffin g, jackson hc, procter mj, rasamison cm, tang-christensen m, widdowson ps, williams gm, reynet c.deorphanization of a g protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. cell metab. 2006 mar;3(3):167-75
PSN632408Supplier
- Tel
- 21-57721279 18121011378
- sales@shydchem.com.cn
- Tel
- 021-58950125
- info@chemexpress.com
- Tel
- 021-58955995
- sales@medchemexpress.cn
- Tel
- 0551-66399836 18955197623
- sales@enlipharma.com
- Tel
- 0512-87182056 18013166090
- lingling.qi@yacoo.com.cn